A CD4+ count below 200 cells/μL, advanced age at antiretroviral therapy initiation, and protease inhibitor use were associated with low-level viremia and increased risk for virologic failure among ...
For adults with virologically suppressed HIV-1, once-weekly oral islatravir-lenacapavir (ISL/LEN) is noninferior to ...
Most women living with HIV achieved an immunologic response after 2 years of initiating antiretroviral therapy. A higher baseline HIV viral load increased the odds of an immunologic response in women ...
A once-weekly HIV pill combining the antiretroviral drugs islatravir and lenacapavir is as effective as a widely used ...
A once-weekly oral HIV treatment maintained viral suppression as effectively as a standard once-daily regimen in a phase 3 ...
Reviewed by Carrie D. Johnston, MD, MS, Assistant Professor in the Division of Infectious Diseases at Weill Cornell Medical College in New York City. "Medical Journeys" is a set of clinical resources ...
The difference between regimens met the trial's noninferiority threshold ...